Prognostic implications of altered human epidermal growth factor receptors (HERs) in gastric carcinomas: HER2 and HER3 are predictors of poor outcome

Journal of Clinical Oncology

Volumn 29, Issue 22, 2011, Pages 3030-3036

  Begnami, Maria D ^a   Fukuda, Emy ^a   Fregnani, José H T G ^b   Nonogaki, Suely ^a   Montagnini, André L ^a   Da Costa Jr , Wilson L ^a   Soares, Fernando A ^a  

^a Institute Adolpho Lutz   (Brazil)

^b Hospital Do Cancer de Barretos   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIDERMAL GROWTH FACTOR RECEPTOR 3; EPIDERMAL GROWTH FACTOR RECEPTOR 4; HER2 PROTEIN, HUMAN; TUMOR MARKER;

ADULT; AGED; ARTICLE; CANCER GROWTH; CANCER INVASION; CANCER STAGING; CORRELATION ANALYSIS; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE AMPLIFICATION; GENE EXPRESSION PROFILING; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; STOMACH CARCINOMA; SURVIVAL RATE; TISSUE MICROARRAY; CARCINOMA; GENE EXPRESSION REGULATION; KAPLAN MEIER METHOD; METABOLISM; METASTASIS; MIDDLE AGED; MORTALITY; MULTIVARIATE ANALYSIS; PATHOLOGY; PREDICTIVE VALUE; PROTEIN MULTIMERIZATION; STOMACH TUMOR; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION, FLUORESCENCE; KAPLAN-MEIER ESTIMATE; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM INVASIVENESS; NEOPLASM STAGING; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROTEIN MULTIMERIZATION; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, ERBB-2; RECEPTOR, ERBB-3; STOMACH NEOPLASMS; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 80051647503     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2010.33.6313     Document Type: Article

References (69)

1. Olayioye MA, Neve RM, Lane HA, et al: The ErbB signaling network: Receptor heterodimerization in development and cancer. EMBO J 19:3159-3167, 2000 (Pubitemid 30428195)
2. Hynes NE, Lane HA: ERBB receptors and cancer: The complexity of targeted inhibitors. Nat Rev Cancer 5:341-354, 2005 (Pubitemid 40637826)
3. Normanno N, Bianco C, Strizzi L, et al: The ErbB receptors and their ligands in cancer: An overview. Curr Drug Targets 6:243-257, 2005 (Pubitemid 40667793)
4. Riely GJ, Politi KA, Miller VA, et al: Update on epidermal growth factor receptor mutations in non-small cell lung cancer. Clin Cancer Res 12:7232-7241, 2006 (Pubitemid 46095394)
5. Tzahar E, Waterman H, Chen X, et al: A hierarchical network of interreceptor interactions determines signal transduction by Neu differentiation factor/neuregulin and epidermal growth factor. Mol Cell Biol 16:5276-5287, 1996 (Pubitemid 26315047)
6. Sato-Kuwabara Y, Neves JI, Fregnani JH, et al: Evaluation of gene amplification and protein expression of HER-2/neu in esophageal squamous cell carcinoma using fluorescence in situ hybridization (FISH) and immunohistochemistry. BMC Cancer 9:6, 2009
7. Slamon DJ, Godolphin W, Jones LA, et al: Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 244:707-712, 1989 (Pubitemid 19147683)
8. Jewell E, Secord AA, Brotherton T, et al: Use of trastuzumab in the treatment of metastatic endometrial cancer. Int J Gynecol Cancer 16:1370-1373, 2006 (Pubitemid 43886771)
9. Tanner B, Hasenclever D, Stern K, et al: ErbB-3 predicts survival in ovarian cancer. J Clin Oncol 24:4317-4323, 2006 (Pubitemid 46630790)
10. Koumakpayi IH, Diallo JS, Le Page C, et al: Expression and nuclear localization of ErbB3 in prostate cancer. Clin Cancer Res 12:2730-2737, 2006
11. Gollamudi M, Nethery D, Liu J, et al: Autocrine activation of ErbB2/ErbB3 receptor complex by NRG-1 in non-small cell lung cancer cell lines. Lung Cancer 43:135-143, 2004 (Pubitemid 38114741)
12. Srinivasan R, Benton E, McCormick F, et al: Expression of the c-erbB-3/HER-3 and c-erbB-4/HER-4 growth factor receptors and their ligands, neuregulin-1 alpha, neuregulin-1 beta, and betacellulin, in normal endometrium and endometrial cancer. Clin Cancer Res 5:2877-2883, 1999 (Pubitemid 29493966)
13. Sartor CI, Zhou H, Kozlowska E, et al: Her4 mediates ligand-dependent antiproliferative and differentiation responses in human breast cancer cells. Mol Cell Biol 21:4265-4275, 2001 (Pubitemid 32565308)
14. Naresh A, Long W, Vidal GA, et al: The ERBB4/HER4 intracellular domain 4ICD is a BH3-only protein promoting apoptosis of breast cancer cells. Cancer Res 66:6412-6420, 2006
15. García I, Vizoso F, Martin A, et al: Clinical significance of the epidermal growth factor receptor and HER2 receptor in resectable gastric cancer. Ann Surg Oncol 10:234-241, 2003 (Pubitemid 40486955)
16. Allgayer H, Babic R, Gruetzner KU, et al: C-erbB-2 is of independent prognostic relevance in gastric cancer and is associated with the expression of tumor-associated protease systems. J Clin Oncol 18:2201-2209, 2000 (Pubitemid 30350211)
17. Ross JS, McKenna BJ: The HER-2/neu oncogene in tumors of the gastrointestinal tract. Cancer Invest 19:554-568, 2001 (Pubitemid 32619394)
18. Hayashi M, Inokuchi M, Takagi Y, et al: High expression of HER3 is associated with a decreased survival in gastric cancer. Clin Cancer Res 14:7843-7849, 2008
19. Kataoka H, Joh T, Kasugai K, et al: Expression of mRNA for heregulin and its receptor, ErbB-3 and ErbB-4, in human upper gastrointestinal mucosa. Life Sci 63:553-564, 1998 (Pubitemid 28355818)
20. Kononen J, Bubendorf L, Kallioniemi A, et al: Tissue microarrays for high-throughput molecular profiling of tumor specimens. Nat Med 4:844-847, 1998 (Pubitemid 28331029)
21. Kim MA, Lee HS, Lee HE, et al: EGFR in gastric carcinomas: Prognostic significance of protein overexpression and high gene copy number. Histopathology 52:738-746, 2008 (Pubitemid 351600058)
22. Hofmann M, Stoss O, Shi D, et al: Assessment of a HER2 scoring system for gastric cancer: Results from a validation study. Histopathology 52:797-805, 2008 (Pubitemid 351724903)
23. Rajkumar T, Stamp GW, Pandha HS, et al: Expression of the type 1 tyrosine kinase growth factor receptors EGF receptor, c-erbB2 and c-erbB3 in bladder cancer. J Pathol 179:381-385, 1996 (Pubitemid 26276106)
24. Marx AH, Tharun L, Muth J, et al: HER-2 amplification is highly homogenous in gastric cancer. Hum Pathol 40:769-777, 2009
25. Schraml P, Kononen J, Bubendorf L, et al: Tissue microarrays for gene amplification surveys in many different tumor types. Clin Cancer Res 5:1966-1975, 1999 (Pubitemid 29399245)
26. Bubendorf L, Kononen J, Koivisto P, et al: Survey of gene amplifications during prostate cancer progression by high-throughout fluorescence in situ hybridization on tissue microarrays. Cancer Res 59:803-806, 1999 (Pubitemid 29086730)
27. Parkin DM: International variation. Oncogene 23:6329-6340, 2004
28. Kamangar F, Dores GM, Anderson WF: Patterns of cancer incidence, mortality, and prevalence across five continents: Defining priorities to reduce cancer disparities in different geographic regions of the world. J Clin Oncol 24:2137-2150, 2006 (Pubitemid 46655601)
29. Cervantes A, Roselló S, Roda D, et al: The treatment of advanced gastric cancer: Current strategies and future perspectives. Ann Oncol 19:v103-v107, 2008 (suppl 5)
30. Bilous M, Osamura RY, Rüschoff J, et al: HER-2 amplification is highly homogenous in gastric cancer. Hum Pathol 41:304-305, 2010; author reply 305-306
31. Hirsch FR, Varella-Garcia M, Bunn PA Jr, et al: Epidermal growth factor receptor in non-small-cell lung carcinomas: Correlation between gene copy number and protein expression and impact on prognosis. J Clin Oncol 21:3798-3807, 2003 (Pubitemid 46606235)
32. Shia J, Klimstra DS, Li AR, et al: Epidermal growth factor receptor expression and gene amplification in colorectal carcinoma: An immunohistochemical and chromogenic in situ hybridization study. Mod Pathol 18:1350-1356, 2005 (Pubitemid 41348654)
33. Wang X, Zhang S, MacLennan GT, et al: Epidermal growth factor receptor protein expression and gene amplification in small cell carcinoma of the urinary bladder. Clin Cancer Res 13:953-957, 2007 (Pubitemid 46340372)
34. Perez EA: The role of adjuvant monoclonal antibody therapy for breast cancer: Rationale and new studies. Curr Oncol Rep 3:516-522, 2001
35. Ekberg T, Nestor M, Engström M, et al: Expression of EGFR, HER2, HER3, and HER4 in metastatic squamous cell carcinomas of the oral cavity and base of tongue. Int J Oncol 26:1177-1185, 2005
36. Wang KL, Wu TT, Choi IS, et al: Expression of epidermal growth factor receptor in esophageal and esophagogastric junction adenocarcinomas: Association with poor outcome. Cancer 109:658-667, 2007 (Pubitemid 46233226)
37. Kimura M, Tsuda H, Morita D, et al: A proposal for diagnostically meaningful criteria to classify increased epidermal growth factor receptor and c-erbB-2 gene copy numbers in gastric carcinoma, based on correlation of fluorescence in situ hybridization and immunohistochemical measurements. Virchows Arch 445:255-262, 2004 (Pubitemid 39286893)
38. Lemoine NR, Jain S, Silvestre F, et al: Amplification and overexpression of the EGF receptor and c-erbB-2 proto-oncogenes in human stomach cancer. Br J Cancer 64:79-83, 1991
39. Yasui W, Sumiyoshi H, Hata J, et al: Expression of epidermal growth factor receptor in human gastric and colonic carcinomas. Cancer Res 48:137-141, 1988 (Pubitemid 18030342)
40. Matsubara J, Yamada Y, Hirashima Y, et al: Impact of insulin-like growth factor type 1 receptor, epidermal growth factor receptor, and HER2 expressions on outcomes of patients with gastric cancer. Clin Cancer Res 14:3022-3029, 2008
41. García I, Vizoso F, Andicoechea A, et al: Clinical significance of epidermal growth factor receptor content in gastric cancer. Int J Biol Markers 16:183-188, 2001 (Pubitemid 33039924)
42. Liang Z, Zeng X, Gao J, et al: Analysis of EGFR, HER2, and TOP2A gene status and chromosomal polysomy in gastric adenocarcinoma from Chinese patients. BMC Cancer 8:363, 2008
43. Takehana T, Kunitomo K, Kono K, et al: Status of c-erbB-2 in gastric adenocarcinoma: A comparative study of immunohistochemistry, fluorescence in situ hybridization and enzyme-linked immunosorbent assay. Int J Cancer 98:833-837, 2002 (Pubitemid 34286677)
44. Park DI, Yun JW, Park JH, et al: HER-2/neu amplification is an independent prognostic factor in gastric cancer. Dig Dis Sci 51:1371-1379, 2006 (Pubitemid 44315804)
45. Tanner M, Hollmén M, Junttila TT, et al: Amplification of HER-2 in gastric carcinoma: Association with topoisomerase IIalpha gene amplification, intestinal type, poor prognosis and sensitivity to trastuzumab. Ann Oncol 16:273-278, 2005 (Pubitemid 40309309)
46. Yan B, Yau EX, Bte Omar SS, et al: A study of HER2 gene amplification and protein expression in gastric cancer. J Clin Pathol 63:839-842, 2010
47. Gravalos C, Jimeno A: HER2 in gastric cancer: A new prognostic factor and a novel therapeutic target. Ann Oncol 19:1523-1529, 2008
48. Bang YJ, Van Cutsem E, Feyereislova A, et al: Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): A phase 3, open-label, randomised controlled trial. Lancet 376:687-697, 2010
49. Wolff AC, Hammond ME, Schwartz JN, et al: American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol 25:118-145, 2007 (Pubitemid 350003059)
50. Rüschoff J, Dietel M, Baretton G, et al: HER2 diagnostics in gastric cancer: Guideline validation and development of standardized immunohistochemical testing. Virchows Arch 457:299-307, 2010
51. Sasano H, Date F, Imatani A, et al: Double immunostaining for c-erbB-2 and p53 in human stomach cancer cells. Hum Pathol 24:584-589, 1993 (Pubitemid 23162224)
52. Tateishi M, Toda T, Minamisono Y, et al: Clinicopathological significance of c-erbB-2 protein expression in human gastric carcinoma. J Surg Oncol 49:209-212, 1992
53. Sergina NV, Rausch M, Wang D, et al: Escape from HER-family tyrosine kinase inhibitor therapy by the kinase-inactive HER3. Nature 445:437-441, 2007 (Pubitemid 46160912)
54. Sanidas EE, Filipe MI, Linehan J, et al: Expression of the c-erbB-3 gene product in gastric cancer. Int J Cancer 54:935-940, 1993 (Pubitemid 23267465)
55. Offterdinger M, Schöfer C, Weipoltshammer K, et al: C-erbB-3: A nuclear protein in mammary epithelial cells. J Cell Biol 157:929-939, 2002 (Pubitemid 34839768)
56. Wang SC, Lien HC, Xia W, et al: Binding at and transactivation of the COX-2 promoter by nuclear tyrosine kinase receptor ErbB-2. Cancer Cell 6:251-261, 2004 (Pubitemid 39222038)
57. Kapitanović S, Radosević S, Slade N, et al: Expression of erbB-3 protein in colorectal adenocarcinoma: Correlation with poor survival. J Cancer Res Clin Oncol 126:205-211, 2000 (Pubitemid 30183023)
58. Abd El-Rehim DM, Pinder SE, Paish CE, et al: Expression and co-expression of the members of the epidermal growth factor receptor (EGFR) family in invasive breast carcinoma. Br J Cancer 91:1532-1542, 2004 (Pubitemid 39486359)
59. Wei Q, Sheng L, Shui Y, et al: EGFR, HER2, and HER3 expression in laryngeal primary tumors and corresponding metastases. Ann Surg Oncol 15:1193-1201, 2008
60. Wei Q, Chen L, Sheng L, et al: EGFR, HER2 and HER3 expression in esophageal primary tumours and corresponding metastases. Int J Oncol 31:493-499, 2007
61. Witton CJ, Reeves JR, Going JJ, et al: Expression of the HER1-4 family of receptor tyrosine kinases in breast cancer. J Pathol 200:290-297, 2003 (Pubitemid 36827302)
62. Aubele M, Auer G, Walch AK, et al: PTK (protein tyrosine kinase)-6 and HER2 and 4, but not HER1 and 3 predict long-term survival in breast carcinomas. Br J Cancer 96:801-807, 2007 (Pubitemid 46376621)
63. Sassen A, Rochon J, Wild P, et al: Cytogenetic analysis of HER1/EGFR, HER2, HER3 and HER4 in 278 breast cancer patients. Breast Cancer Res 10:R2, 2008
64. Junttila TT, Sundvall M, Lundin M, et al: Cleavable ErbB4 isoform in estrogen receptor-regulated growth of breast cancer cells. Cancer Res 65:1384-1393, 2005 (Pubitemid 40270166)
65. Yarden Y, Sliwkowski MX: Untangling the ErbB signalling network. Nat Rev Mol Cell Biol 2:127-137, 2001 (Pubitemid 33674041)
66. Berger MB, Mendrola JM, Lemmon MA: ErbB3/HER3 does not homodimerize upon neuregulin binding at the cell surface. FEBS Lett 569:332-336, 2004 (Pubitemid 38849407)
67. Lee D, Yu M, Lee E, et al: Tumor-specific apoptosis caused by deletion of the ERBB3 pseudokinase in mouse intestinal epithelium. J Clin Invest 119:2702-2713, 2009
68. Hsieh AC, Moasser MM: Targeting HER proteins in cancer therapy and the role of the non-target HER3. Br J Cancer 97:453-457, 2007 (Pubitemid 47258458)
69. Baselga J, Swain SM: Novel anticancer targets: Revisiting ERBB2 and discovering ERBB3. Nat Rev Cancer 9:463-475, 2009